Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Free Cash Flow: 2019-2024

Historic Free Cash Flow for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to -$65.3 million.

  • C4 Therapeutics' Free Cash Flow fell 30.63% to -$31.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$94.8 million, marking a year-over-year decrease of 32.42%. This contributed to the annual value of -$65.3 million for FY2024, which is 39.81% up from last year.
  • Per C4 Therapeutics' latest filing, its Free Cash Flow stood at -$65.3 million for FY2024, which was up 39.81% from -$108.5 million recorded in FY2023.
  • C4 Therapeutics' Free Cash Flow's 5-year high stood at -$65.3 million during FY2024, with a 5-year trough of -$111.4 million in FY2022.
  • For the 3-year period, C4 Therapeutics' Free Cash Flow averaged around -$95.1 million, with its median value being -$108.5 million (2023).
  • Per our database at Business Quant, C4 Therapeutics' Free Cash Flow tumbled by 225.12% in 2020 and then surged by 39.81% in 2024.
  • Yearly analysis of 5 years shows C4 Therapeutics' Free Cash Flow stood at -$67.9 million in 2020, then decreased by 29.96% to -$88.2 million in 2021, then declined by 26.28% to -$111.4 million in 2022, then increased by 2.59% to -$108.5 million in 2023, then surged by 39.81% to -$65.3 million in 2024.